Heart failure medications (diuretics, ACE/ARB inhibitors, mineralocorticoid receptor antagonists {MRA}, and beta-blockers) are indicated in the patients presenting with right/left ventricular failure with the primary diagnosis of ARVD as they improve the symptoms of heart failure and retard the progression of ARVD [33,34]. Here, NR3C2 is linked to arrhythmogenic right ventricular cardiomyopathy.